期刊文献+

白蛋白纳米球药物载体的制备及表征 被引量:8

Preparation and Characterization of Albumin Nanospheres as Drug Carrier
下载PDF
导出
摘要 以超声乳化-化学交联方法制备了粒径为60~100 nm的负载丝裂霉素的白蛋白纳米球.含有丝裂霉素和白蛋白的水相经超声乳化,在油相中形成纳米乳滴,然后加入戊二醛,使纳米乳滴发生交联形成纳米球.通过比较形成乳液的稳定性选择了最适的乳化剂,系统考察了交联剂戊二醛的用量对所制纳米球性质的影响.结果表明,戊二醛用量增加,则纳米球产率、载药量和药物包封率均增加,而粒径和溶胀度下降,体外释药速度亦下降.戊二醛用量使醛基与白蛋白氨基摩尔比为16:1时最佳.纳米球的体外释药为双相释药,两个释药相均符合Higuchi方程. Mitomycin-loaded albumin nanospheres sized between 60 and 100 nm were prepared by the ultrasonic emulsification-crosslinking method. After the albumin aqueous phase containing mitomycin was emulsified into the oil phase by the ultrasonifier to obtain the nanodroplets, glutaraldehyde was added to crosslink the nanodroplets. The optimal emulsifier was chosen by comparing the stability of emulsion prepared with various emulsifiers. It was found that the most stable W/O emulsion was obtained when Arlacel 83 was used as the emulsifier. The influence of the amount of glutataldehyde on the properties of the albumin nanospheres was investigated. It was found that the yield and drug content of nanospheres and loading efficiency of the drug increased, while the diameter and swelling degree of nanospheres, and the rate of drug release in vitro decreased, with the increase of the amount of gluataraldehyde. The optimal amount of glutaraldehyde corresponds to the ratio of aldehyde group to amino group being 16:1. The drug release in vitro can be divided into two phases, both of which can be expressed with the Higuchi equation.
作者 王恺 马光辉
出处 《过程工程学报》 EI CAS CSCD 北大核心 2004年第2期155-159,共5页 The Chinese Journal of Process Engineering
基金 国家杰出青年科学基金资助项目(编号:20125616)
关键词 白蛋白纳米球 制备 体外释药 丝裂霉素 表征 抗癌药物 靶向制剂 albumin nanospheres preparation in vitro drug release mitomycin
  • 相关文献

参考文献12

  • 1徐希明,张钧寿.氟尿嘧啶白蛋白微球的制备及体外性质研究[J].中国药科大学学报,1999,30(5):353-356. 被引量:9
  • 2吴镭,平其能主编..药剂学发展与展望[M].北京:化学工业出版社,2002:149.
  • 3Müller B G, Leuenberger H, Kissel T. Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique [J]. Pharm. Res., 1996, 13(1): 32-37. 被引量:1
  • 4Lin W, Garnett M C, Schacht E, et al. Preparation and in vitro Characterization of HSA-mPEG Nanoparticles [J]. Int. J. Pharm.,1999, 189: 161-170. 被引量:1
  • 5Lin W, Gamett M C, Davis S S, et al. Preparation and Characterization of Rose Bengal-loaded Surface-modified Albumin Nanoparticles [J]. J. Control. Rel., 2001, 71:117-126. 被引量:1
  • 6Coombes A G A, Breeze V, Lin W, et al. Lactic Acid-stabilised Albumin for Microsphere Formulation and Biomedical Coatings [J]. Biomaterials, 2001,22: 1-8. 被引量:1
  • 7Chen G O, Lin W, Coombes A G A, et al. Preparation of Human Serum Albumin Microspheres by a Novel Acetone-heat Denaturation Method [J]. J. Microencapsul., 1994, 11 (4): 395-407. 被引量:1
  • 8Gupta P K, Hung C T, Lam F C. Factorial Design Based Optimization of the Formulation of Albumin Microspheres Containing Adriamycin [J]. J. Microencapsul., 1989, 6(2): 147-160. 被引量:1
  • 9Durbin D P, El-Aasser M S, Poehlein G W, et al. Influence of Monomer Preemulsification on Formation of Particles from Monomer Drop in Emulsion Polymerization [J]. J. Appl. Polymer. Sci., 1979, 24: 703-707. 被引量:1
  • 10Landfester K, Willert M, Antonietti M. Preparation of Polymer Particles in Nonaqueous Direct and Inverse Miniemulsions [J].Macromolecules, 2000, 33: 2370-2376. 被引量:1

二级参考文献8

共引文献8

同被引文献107

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部